Keyword: Intercept Pharmaceuticals
As Genfit hopes for phase 3 successes and filings for its liver disease drug, its CEO and co-founder Jean-François Mouney is stepping aside.
Already on the Euronext stock exchange, liver disease biotech GenFit has made the jump to the more lucrative Nasdaq with a $135 million IPO.
In a pivotal phase 3 study, Intercept Pharmaceuticals' obeticholic acid improved liver fibrosis without any worsening of NASH after 18 months.
The ASK1 inhibitor was no better than placebo at improving fibrosis, wiping out hopes that selonsertib would spearhead Gilead’s push into a new field.
Arcturus Therapeutics and its ousted CEO Joseph Payne agreed to end litigation against each other.
Arcturus is losing its second executive in as many weeks: CSO/COO Pad Chivukula, who will take an advisory role.
Metacrine is adding to this week's NASH talk after getting off a series B as it aims to combat the fatty liver disorder.
In new phase 2 data published today, Gilead says a higher dose of its NASH drug saw statistically significant reductions in liver fat.
The cash injection will also position Genfit to look to life beyond the phase 3 by supporting commercial preparations and the in-licensing of assets.
French biotech Genfit, a leader in the race to sell a new med for fatty liver disease, said in its financials that it will delay its phase 3 NASH trial in patients with liver scarring by four to six months.